Clinical Trial

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-05-31; most recent amendment 2025-09-22.
Trial Details
NCT Number NCT04912765
Lead Sponsor National Cancer Centre, Singapore
Collaborators: Bristol-Myers Squibb
Conditions Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Enrollment 60 participants
Start Date 2021-04-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31